One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Lymph Node Tumor Burden Correlates With Tumor Budding and Poorly Differentiated Clusters: A New Prognostic Factor in Colorectal Carcinoma?
Archilla, Ivan MD1; Díaz-Mercedes, Sherley MD1; Aguirre, José Javier MD, PhD2; Tarragona, Jordi MD, PhD3; Machado, Isidro MD, PhD4; Rodrigo, Maria Teresa MD1; Lopez-Prades, Sandra MSc1; Gorostiaga, Iñigo MD2; Landolfi, Stefania MD5; Alén, Begoña Otero PhD6; Balaguer, Francesc MD, PhD7,8; Castells, Antoni MD, PhD7,8; Camps, Jordi PhD7,8; Cuatrecasas, Miriam MD, PhD1,8
doi : 10.14309/ctg.0000000000000303
March 2021 - Volume 12 - Issue 3 - p e00303
Molecular lymph node (LN) staging in early colorectal cancer (CRC) has demonstrated to be more precise than conventional histopathology pN staging. Tumor budding (TB) and poorly differentiated clusters (PDCs) are associated with LN metastases, recurrences, and lower survival in CRC. We evaluated the correlation between the total tumor load (TTL) in LNs from CRC surgical specimens with patient outcome, TB, and PDC.
Smoking, Genetic Predisposition, and Colorectal Cancer Risk
Chen, Xuechen PhD1,2; Jansen, Lina PhD1; Guo, Feng PhD1,2; Hoffmeister, Michael PhD1; Chang-Claude, Jenny PhD3,4; Brenner, Hermann MD, MPH1,5,6
doi : 10.14309/ctg.0000000000000317
March 2021 - Volume 12 - Issue 3 - p e00317
Smoking and genetic predisposition are established risk factors for colorectal cancer (CRC). We aimed to assess and compare their individual and joint impact on CRC risk using the novel approach of genetic risk equivalent (GRE).
Risk Stratification Score Improves Sensitivity for Advanced Colorectal Neoplasia in Colorectal Cancer Screening: The Oshima Study Workgroup
Sekiguchi, Masau MD, PhD1,2,3; Kakugawa, Yasuo MD3; Ikematsu, Hiroaki MD, PhD4; Hotta, Kinichi MD5; Konda, Kenichi MD, PhD6; Tanaka, Yusaku MD7; Takamaru, Hiroyuki MD, PhD3; Yamada, Masayoshi MD, PhD3; Sakamoto, Taku MD, PhD3; Saito, Yutaka MD, PhD3; Imai, Kenichiro MD5; Ito, Sayo MD5; Koga, Yoshikatsu MD, PhD8; Iwasaki, Motoki MD, PhD9; Murakami, Yoshitaka PhD10; Matsuda, Takahisa MD, PhD1,2,3
doi : 10.14309/ctg.0000000000000319
March 2021 - Volume 12 - Issue 3 - p e00319
Noninvasive colorectal cancer (CRC) screening methods with higher sensitivity for advanced colorectal neoplasia (ACN) than the fecal immunochemical test (FIT) alone are warranted. This study aimed to elucidate the diagnostic performance of a risk stratification score calculated using baseline individual characteristics and its combination with FIT for detecting ACN.
Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial
Charatcharoenwitthaya, Phunchai MD1; Kuljiratitikal, Kraisingh MD1; Aksornchanya, Ophas MS2; Chaiyasoot, Kusuma MD3; Bandidniyamanon, Wimolrak MS1; Charatcharoenwitthaya, Natthinee MD4
doi : 10.14309/ctg.0000000000000316
March 2021 - Volume 12 - Issue 3 - p e00316
This randomized trial aimed to compare the effects of moderate-intensity aerobic vs resistance exercise with dietary modification in patients with nonalcoholic fatty liver disease (NAFLD).
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
Hui, Vicki Wing-Ki BSc1,2,3; Yip, Terry Cheuk-Fung PhD1,2,3; Wong, Vincent Wai-Sun MD1,2,3; Tse, Yee-Kit MPhil1,2,3; Chan, Henry Lik-Yuen MD1,2,3; Lui, Grace Chung-Yan MD1,2,4; Wong, Grace Lai-Hung MD1,2,3
doi : 10.14309/ctg.0000000000000324
March 2021 - Volume 12 - Issue 3 - p e00324
Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment. We aimed to investigate the impact of aspirin on reducing HCC risk in patients treated with first-line oral nucleos(t)ide analogs (NAs; entecavir and/or tenofovir disoproxil fumarate).
Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study
Gao, Feng MD1; Zheng, Kenneth I. MD2; Chen, Sui-Dan MD3; Lee, Dong Hyeon MD4; Wu, Xi-Xi MD1; Wang, Xiao-Dong MD2; Targher, Giovanni MD, PhD5; Byrne, Christopher D. MD, PhD6; Chen, Yong-Ping MD2,7,8; Kim, Won MD, PhD4; Zheng, Ming-Hua MD, PhD2,7,8
doi : 10.14309/ctg.0000000000000321
March 2021 - Volume 12 - Issue 3 - p e00321
Strong evidence indicates that multiple genetic and environmental risk factors play a role in the pathogenesis of nonalcoholic steatohepatitis (NASH). We aimed to develop and validate a novel nomogram, incorporating both genetic and clinical factors, for predicting NASH.
Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis
Bossen, Lars MD1; Vesterhus, Mette MD, PhD2,3,4; Hov, Johannes R. MD, PhD2,5,6,7; Färkkilä, Martti MD, PhD8; Rosenberg, William M. MA, MBBS, DPhil, FRCP9; Møller, Holger J. MD, PhD, DMSc10; Boberg, Kirsten M. MD, PhD2,5,6,7; Karlsen, Tom H. MD, PhD2,5,6,7; Grønbæk, Henning MD, PhD1
doi : 10.14309/ctg.0000000000000315
March 2021 - Volume 12 - Issue 3 - p e00315
Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by bile duct inflammation and fibrosis. The role of macrophages in PSC development and progression is less studied. Macrophage activation markers soluble (s)CD163 and mannose receptor (sMR) are associated with disease severity and outcome in other liver diseases, but not previously investigated in PSC. We evaluated sCD163 and sMR regarding disease severity and prognosis in patients with PSC.
Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease
Pinto-Lopes, Pedro MD, MSc1,2,3; Melo, Francisco MD, MSc3; Afonso, Joana PhD3,4; Pinto-Lopes, Rui MD, MSc5; Rocha, Cátia MSc3,6; Melo, Daniel MD, MSc7; Macedo, Guilherme MD, PhD8; Dias, Cláudia Camila PhD9,10; Carneiro, Fátima MD, PhD7,11; Magro, Fernando MD, PhD3,4,8,12; for the Portuguese IBD Study Group (GEDII)
doi : 10.14309/ctg.0000000000000320
March 2021 - Volume 12 - Issue 3 - p e00320
Dipeptidyl peptidase-4 (DPP-4) is a membrane-bound glycoprotein that acts as a receptor but also exists in a soluble form. It has been recognized as a mediator of inflammation and considered a biomarker in inflammatory bowel disease (IBD).
Correction to: Disparities in the Diagnosis and Treatment of Gastric Cancer in Relation to Disabilities
Kim, Hyoung Woo MD; Shin, Dong Wook MD, DrPH, MBA; Yeob, Kyoung Eun MPH, PhD; Cho, In Young MD; Kim, So Young MD, PhD; Park, Seon Mee MD, PhD; Park, Jong Heon MD, PhD; Park, Jong Hyock MD, MPH, PhD; Kawachi, Ichiro MD, PhD
doi : 10.14309/ctg.0000000000000322
March 2021 - Volume 12 - Issue 3 - p e00322
